About OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to 3q23 rearrangement syndrome
OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to 3q23 rearrangement syndrome is a rare disease catalogued by Orphanet (ORPHA:261559). Search below for active recruiting clinical trials from ClinicalTrials.gov, or visit the Orphanet expert page for specialist centres, natural history studies, and patient registries worldwide.
Clinical Trial Eligibility Tips
What to know before applying to OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to 3q23 rearrangement syndrome trials.
Search ClinicalTrials.gov for "OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to 3q23 rearrangement syndrome" or Orphanet code ORPHA:261559 to find disease-specific recruiting studies.
Ask your specialist to refer you to an Orphanet-accredited Centre of Expertise for this condition.
Natural history studies and patient registries often open enrolment before drug trials — contact the Orphanet patient community first.
Patient Resources
Find recruiting OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to 3q23 rearrangement syndrome trials
Search 500,000+ studies from ClinicalTrials.gov, filtered for OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to 3q23 rearrangement syndrome. Updated daily.